CY1124929T1 - 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139 - Google Patents

4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139

Info

Publication number
CY1124929T1
CY1124929T1 CY20211101111T CY211101111T CY1124929T1 CY 1124929 T1 CY1124929 T1 CY 1124929T1 CY 20211101111 T CY20211101111 T CY 20211101111T CY 211101111 T CY211101111 T CY 211101111T CY 1124929 T1 CY1124929 T1 CY 1124929T1
Authority
CY
Cyprus
Prior art keywords
gpr139
benzotriazines
regulators
dihydro
oxo
Prior art date
Application number
CY20211101111T
Other languages
English (en)
Inventor
Stephan HITCHCOCK
Betty Lam
Holger Monenschein
Holly REICHARD
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1124929T1 publication Critical patent/CY1124929T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια μέθοδο για την αντιμετώπιση μιας νόσου, διαταραχής ή κατάστασης που σχετίζεται με το GPR139 χρησιμοποιώντας χημικές ενώσεις του τύπου 1: οι οποίες είναι αγωνιστές του GPR139, ορισμένες χημικές ενώσεις που περιλαμβάνονται από τον τύπο 1, φαρμακευτικές συνθέσεις αυτών, μεθόδους παρασκευής των χημικών ενώσεων και των ενδιάμεσων αυτών.
CY20211101111T 2014-11-20 2021-12-17 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139 CY1124929T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25
PCT/US2015/061607 WO2016081736A1 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
EP15816275.0A EP3221298B1 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139

Publications (1)

Publication Number Publication Date
CY1124929T1 true CY1124929T1 (el) 2023-01-05

Family

ID=55022667

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100646T CY1122613T1 (el) 2014-11-20 2019-06-20 Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
CY20211101111T CY1124929T1 (el) 2014-11-20 2021-12-17 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100646T CY1122613T1 (el) 2014-11-20 2019-06-20 Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139

Country Status (40)

Country Link
US (5) US9556130B2 (el)
EP (2) EP3536324B1 (el)
JP (2) JP6637501B2 (el)
KR (1) KR102582021B1 (el)
CN (2) CN107108531B (el)
AU (1) AU2015349866B2 (el)
BR (1) BR112017010311A2 (el)
CA (1) CA2968242C (el)
CL (1) CL2017001292A1 (el)
CO (1) CO2017005959A2 (el)
CR (1) CR20170275A (el)
CY (2) CY1122613T1 (el)
DK (2) DK3536324T3 (el)
DO (1) DOP2017000120A (el)
EA (1) EA033728B1 (el)
EC (1) ECSP17038999A (el)
ES (2) ES2734735T3 (el)
GE (1) GEP20196961B (el)
HR (2) HRP20212009T1 (el)
HU (2) HUE057451T2 (el)
IL (1) IL252311B (el)
JO (1) JO3719B1 (el)
LT (2) LT3221298T (el)
MA (1) MA40993B1 (el)
MD (1) MD3221298T2 (el)
MX (1) MX2017006448A (el)
MY (1) MY187423A (el)
NZ (1) NZ732208A (el)
PE (1) PE20170899A1 (el)
PH (1) PH12017500920A1 (el)
PL (2) PL3221298T3 (el)
PT (2) PT3536324T (el)
RS (2) RS59078B1 (el)
SG (1) SG11201704002UA (el)
SI (2) SI3221298T1 (el)
TN (1) TN2017000196A1 (el)
TW (1) TWI684590B (el)
UA (1) UA120375C2 (el)
UY (1) UY36406A (el)
WO (1) WO2016081736A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
WO2020081538A1 (en) * 2018-10-16 2020-04-23 The Scripps Research Institute Methods related to opioid therapeutics
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
CA3150508A1 (en) 2019-09-16 2021-03-25 Holger Monenschein Azole-fused pyridazin-3(2h)-one derivatives
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
EP4146635A1 (en) * 2020-05-08 2023-03-15 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
JP2023541485A (ja) 2020-09-21 2023-10-02 武田薬品工業株式会社 統合失調症のための処置
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
WO2023165263A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
DE3752141T2 (de) 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
BRPI0413132A (pt) 2003-07-31 2006-10-03 Irm Llc composições e compostos bicìclicos como inibidores de pdf
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2139895A1 (en) * 2007-03-23 2010-01-06 F. Hoffmann-Roche AG Aza-pyridopyrimidinone derivatives
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
US20160022636A1 (en) 2013-03-14 2016-01-28 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
JP6918088B2 (ja) 2021-08-11
IL252311A0 (en) 2017-07-31
ES2897545T3 (es) 2022-03-01
AU2015349866A1 (en) 2017-06-15
TWI684590B (zh) 2020-02-11
AU2015349866B2 (en) 2020-12-03
KR20170084324A (ko) 2017-07-19
SI3221298T1 (sl) 2019-10-30
EA033728B1 (ru) 2019-11-20
CN107108531A (zh) 2017-08-29
CN112062730B (zh) 2023-09-29
DK3536324T3 (da) 2021-10-25
EP3221298B1 (en) 2019-04-03
IL252311B (en) 2020-07-30
MX2017006448A (es) 2017-09-12
US9770450B2 (en) 2017-09-26
LT3536324T (lt) 2021-12-10
JP2020063285A (ja) 2020-04-23
US10159677B2 (en) 2018-12-25
TW201625566A (zh) 2016-07-16
UY36406A (es) 2016-06-30
US9556130B2 (en) 2017-01-31
PH12017500920B1 (en) 2017-11-20
US20170095480A1 (en) 2017-04-06
ES2734735T3 (es) 2019-12-11
US20160145218A1 (en) 2016-05-26
NZ732208A (en) 2023-02-24
HRP20191003T1 (hr) 2019-08-23
RS62563B1 (sr) 2021-12-31
MA40993B1 (fr) 2019-07-31
BR112017010311A2 (pt) 2017-12-26
LT3221298T (lt) 2019-08-12
US10561662B2 (en) 2020-02-18
KR102582021B1 (ko) 2023-09-22
EP3221298A1 (en) 2017-09-27
SI3536324T1 (sl) 2021-12-31
PL3536324T3 (pl) 2022-02-07
SG11201704002UA (en) 2017-06-29
PT3221298T (pt) 2019-06-28
ECSP17038999A (es) 2017-10-31
JP6637501B2 (ja) 2020-01-29
CN112062730A (zh) 2020-12-11
PE20170899A1 (es) 2017-07-12
UA120375C2 (uk) 2019-11-25
PL3221298T3 (pl) 2019-10-31
CR20170275A (es) 2017-10-30
EP3536324B1 (en) 2021-10-06
US11173161B2 (en) 2021-11-16
DK3221298T3 (da) 2019-06-24
US20190070187A1 (en) 2019-03-07
MA40993A (fr) 2017-09-27
HUE057451T2 (hu) 2022-05-28
DOP2017000120A (es) 2017-06-15
TN2017000196A1 (en) 2018-10-19
CY1122613T1 (el) 2021-05-05
EA201791096A1 (ru) 2017-11-30
CO2017005959A2 (es) 2017-10-20
MD3221298T2 (ro) 2019-10-31
CL2017001292A1 (es) 2018-02-16
US20170348319A1 (en) 2017-12-07
JP2017535559A (ja) 2017-11-30
EP3536324A1 (en) 2019-09-11
HRP20212009T1 (hr) 2022-04-01
RS59078B1 (sr) 2019-09-30
PH12017500920A1 (en) 2017-11-20
MY187423A (en) 2021-09-22
CA2968242C (en) 2022-11-08
JO3719B1 (ar) 2021-01-31
HUE044145T2 (hu) 2019-09-30
WO2016081736A1 (en) 2016-05-26
CN107108531B (zh) 2020-10-20
CA2968242A1 (en) 2016-05-26
PT3536324T (pt) 2021-11-10
US20200129518A1 (en) 2020-04-30
GEP20196961B (en) 2019-03-25

Similar Documents

Publication Publication Date Title
CY1124929T1 (el) 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινες ως ρυθμιστες του gpr139
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1124918T1 (el) Ρυθμιστες ccr2
CY1120029T1 (el) Παραγωγα 6-(5-υδροξυ-1η-πυραζολ-1-υλ) νικοτιναμιδιου και χρηση τους ως αναστολεις phd
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
CY1123581T1 (el) Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
CY1121602T1 (el) Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
CO2017000337A2 (es) Derivados de bis(aril)catecol como herbicidas
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
CY1120763T1 (el) Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CL2017000151A1 (es) Derivados de piridona
CY1120812T1 (el) Υποκατεστημενα παραγωγα αζασπειρο(4.5)δεκανιου
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6
CY1121624T1 (el) Παραγωγα 2-αρυλο-4-υδροξυ-1,3-θειαζολιου χρησιμα ως αναστολεις trpm8 για τη θεραπεια της νευραλγιας, του πονου, της χαπ και του ασθματος